Therapeutic decision-making

治疗决策
  • 文章类型: Journal Article
    临床医学的决策理想情况下是基于随机的证据,安慰剂对照试验(RCT)和随后的系统评价和荟萃分析。然而,孤儿病,期望有一个或多个RCT为临床指南提供信息或证明特定治疗是不现实的,随后的治疗虚无主义可能对患者有害.本文讨论了孤儿疾病背景下治疗决策的好处,重点关注原发性硬化性胆管炎(PSC),作为临床预后不良的孤儿疾病的一个例子。PSC是一种罕见的疾病,其特征是胆管的炎症和进行性纤维化。它有很高的肝功能衰竭风险,恶性肿瘤,和损害生活质量的衰弱症状。肝移植是目前唯一延长PSC寿命的干预措施,但这不是治愈性的选择。文章强调了口服万古霉素(OV)治疗PSC患者的潜在益处,在某些情况下,已显示出明显的临床反应并改善了生活质量。然而,由于缺乏支持其使用的RCTs,OV治疗的获得受到限制.从随机对照试验中获得证据的标准要求可能会导致对孤儿疾病患者隐瞒潜在的改变生命和/或挽救生命的治疗。由于难以招募所需的患者队列和有限的商业回报,因此在这些患者人群中进行RCT具有挑战性。提出了一种标准化的“适应性治疗策略”来解决这个问题。这种方法利用了特定治疗方法的最佳可用证据,考虑个体临床反应,并随着时间的推移调整治疗。
    Decision-making in clinical medicine ideally is based upon evidence from randomized, placebo-controlled trials (RCTs) and subsequent systematic reviews and meta-analyses. However, for orphan diseases, the expectation of having one or multiple RCTs that inform clinical guidelines or justify specific treatments can be unrealistic and subsequent therapeutic nihilism can be detrimental to patients. This article discusses the benefits of therapeutic decision-making in the context of orphan diseases, focusing on primary sclerosing cholangitis (PSC) as an example of an orphan disease with poor clinical outcomes. PSC is a rare disorder characterized by inflammation and progressive fibrosis of the bile ducts. It carries a high risk of liver failure, malignancies, and debilitating symptoms that impair quality of life. Liver transplantation is currently the only life-prolonging intervention for PSC, but it is not a curative option. The article highlights the potential benefits of treating PSC patients with oral vancomycin (OV), which has shown significant clinical responses and improved quality of life in some cases. However, access to OV therapy is limited due to the lack of RCTs supporting its use. The standard requirement of having evidence from RCTs may result in withholding potentially life-altering and/or life-saving treatments for patients with orphan diseases. Conducting RCTs is challenging in these patient populations due to difficulties in recruiting the required patient cohorts and limited commercial returns. A standardized \'adaptive treatment strategy\' is proposed to address this. This approach leverages the best available evidence for specific treatments, considers individual clinical responses, and adjusts treatment over time.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    进行了这项研究,以评估(68Ga)标记的前列腺特异性膜抗原(68Ga-PSMA)正电子发射断层扫描和计算机断层扫描(PET-CT)的影响,将其与常规放射学在高危前列腺癌早期分期中的作用进行比较,并计算PSMA评分,评估其在68Ga-PSMAPET-CT报告中的有用性。
    对65例前列腺癌高危病例进行68Ga-PSMAPET-CT分期。在68Ga-PSMAPET-CT发现和PSMA评分导致管理计划改变后,注意到疾病阶段的任何变化。
    在39%的病例中看到PSMA成像后疾病阶段的变化,在>80%的升级病例中注意到高PSMA评分(03),而低得分(0)和(1)在65%和35%的降级个体中看到,分别。在32%(21)的患者中观察到治疗决策的变化。
    68Ga-PSMAPET-CT扫描对高危前列腺癌患者的计划临床管理有重大影响;因此,它们可以用作放射成像工具的替代品,特别是在盆腔淋巴结和远处转移疾病的检测。PSMA评分可以被认为是68Ga-PSMA成像的标准化报告中的有效工具。
    UNASSIGNED: This research study was conducted to evaluate the impact of (68Ga)-tagged prostatic-specific membrane antigen (68Ga-PSMA) positron emission tomography and computed tomography (PET-CT), compare its role with conventional radiology in early staging of high-risk prostate cancer, and calculate the PSMA score evaluating its usefulness in 68Ga-PSMA PET-CT reporting in our patient population.
    UNASSIGNED: 68Ga-PSMA PET-CT of 65 high-risk cases of prostate cancer was performed for staging purpo-ses. Any change in disease stage was noted after 68Ga-PSMA PET-CT findings and PSMA score leading to a change in the management plan.
    UNASSIGNED: Change in disease stage post-PSMA imaging was seen in 39% cases, high PSMA score (03) was noted in > 80% of upstaged cases, while low score (0) and (1) was seen in 65% and 35% down-staged individuals, respectively. Change in therapeutic decision-making was observed in 32% (21) of patients.
    UNASSIGNED: 68Ga-PSMA PET-CT scans have a significant influence on the planned clinical management of high-risk prostate cancer patients; hence, they can be utilized as a replacement for radiological imaging tools, particularly in the detection of pelvic nodal and distant metastatic disease. PSMA score can be considered as an effective tool in standardized reporting of 68Ga-PSMA imaging.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Review
    目的:在许多人群中,使用标示外药物是一种常见的,有时是必要的做法,重要的临床,道德和财务后果,包括潜在的意外伤害或缺乏有效性。没有国际公认的准则来帮助决策者应用研究证据来告知标签外药物的使用。我们旨在批判性地评估当前证据,为标签外使用决策提供信息,并制定共识建议,以改善未来的实践和研究。
    方法:我们进行了范围审查,以总结有关可用的标签外使用指南的文献,包括类型,纳入证据的范围和科学严谨。调查结果为国际多学科专家小组使用修改后的德尔菲程序制定共识建议提供了信息。我们的目标受众包括临床医生,患者和护理人员,研究人员,监管者,赞助商,卫生技术评估机构,付款人和政策制定者。
    结果:我们发现了31个已发表的关于超说明书使用的治疗决策的指导文件。在20条带有一般性建议的指南中,只有35%的人详细说明了所需证据的类型和质量,以及其评估达到合理的过程,关于适当使用的道德决定。没有全球公认的指导。为了优化未来的治疗决策,我们建议:1)寻求严格的科学证据;2)在证据评估和综合方面利用不同的专业知识;3)使用严格的流程制定适当使用的建议;4)将标签外使用与及时进行有临床意义的研究(包括现实世界的证据)联系起来,以迅速解决知识差距;5)促进临床决策者之间的伙伴关系,研究人员,监管者,政策制定者,和赞助商,以促进这些建议的协调一致的执行和评估。
    结论:我们提供全面的共识建议,以优化超说明书用药的治疗决策,同时推动临床相关研究。成功实施需要适当的资金和基础设施支持,以吸引必要的利益攸关方参与并促进相关伙伴关系,代表了决策者必须紧急应对的重大挑战。本文受版权保护。保留所有权利。
    Off-label medicines use is a common and sometimes necessary practice in many populations, with important clinical, ethical and financial consequences, including potential unintended harm or lack of effectiveness. No internationally recognized guidelines exist to aid decision-makers in applying research evidence to inform off-label medicines use. We aimed to critically evaluate current evidence informing decision-making for off-label use and to develop consensus recommendations to improve future practice and research.
    We conducted a scoping review to summarize the literature on available off-label use guidance, including types, extent and scientific rigor of evidence incorporated. Findings informed the development of consensus recommendations by an international multidisciplinary Expert Panel using a modified Delphi process. Our target audience includes clinicians, patients and caregivers, researchers, regulators, sponsors, health technology assessment bodies, payers and policy makers.
    We found 31 published guidance documents on therapeutic decision-making for off-label use. Of 20 guidances with general recommendations, only 35% detailed the types and quality of evidence needed and the processes for its evaluation to reach sound, ethical decisions about appropriate use. There was no globally recognized guidance. To optimize future therapeutic decision-making, we recommend: (1) seeking rigorous scientific evidence; (2) utilizing diverse expertise in evidence evaluation and synthesis; (3) using rigorous processes to formulate recommendations for appropriate use; (4) linking off-label use with timely conduct of clinically meaningful research (including real-world evidence) to address knowledge gaps quickly; and (5) fostering partnerships between clinical decision-makers, researchers, regulators, policy makers, and sponsors to facilitate cohesive implementation and evaluation of these recommendations.
    We provide comprehensive consensus recommendations to optimize therapeutic decision-making for off-label medicines use and concurrently drive clinically relevant research. Successful implementation requires appropriate funding and infrastructure support to engage necessary stakeholders and foster relevant partnerships, representing significant challenges that policy makers must urgently address.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    治疗推理是当目的,任务,或者从事推理的目标是确定患者的管理计划。由于该领域对治疗推理过程的理解不太清楚,我们专注于收集治疗推理过程数据的研究.综合以前对治疗推理特征的研究,方法论方法,理论基础,和结果。我们进行了范围审查,系统地搜索了没有日期限制的英语文章。数据库包括MEDLINE,CINAHLPlus,Scopus,Embase,Proquest学位论文和论文全球,和ERIC。搜索词捕获了卫生专业教育研究中的治疗推理。初步搜索产生5450篇文章。标题和摘要筛选产生了180篇文章。经过全文审查,本综述包括87项研究。如果文章在卫生专业教育之外,则被排除在外,没有收集治疗推理过程的数据,不是实证研究,或者不专注于治疗推理。我们使用定性内容分析根据范围界定问题分析了所包含的文章。包括1987年至2019年的87篇文章。采用了几种研究设计,包括大声思考方案,面试和书面文件。超过一半的文章使用定性编码分析数据。作者经常利用几种中距离理论来解释治疗推理过程。假设演绎模型是最常被提及的。所包含的文章很少建立在以前研究的结果之上。找到了六个关键的结果类别:确定主题,表征和检验以前的局部理论,探索因素,开发新的地方理论,测试工具,和测试假设。尽管有大量的治疗推理研究,个别研究结果与以前的研究仍然隔离。我们未来的建议包括综合现有的模型,开发新的方法,并研究治疗推理的其他方面。
    Therapeutic reasoning is when the purpose, task, or goal for engaging in reasoning is to determine the patient\'s management plan. As the field\'s understanding of the process of therapeutic reasoning is less well understood, we focused on studies that collected data on the process of therapeutic reasoning. To synthesize previous studies of therapeutic reasoning characteristics, methodological approaches, theoretical underpinnings, and results. We conducted a scoping review with systematic searching for English language articles with no date limits. Databases included MEDLINE, CINAHL Plus, Scopus, Embase, Proquest Dissertations and Theses Global, and ERIC. Search terms captured therapeutic reasoning in health professions education research. Initial search yielded 5450 articles. The title and abstract screening yielded 180 articles. After full-text review, 87 studies were included in this review. Articles were excluded if they were outside health professions education, did not collect data on the process of therapeutic reasoning, were not empirical studies, or not focused on therapeutic reasoning. We analyzed the included articles according to scoping questions using qualitative content analysis. 87 articles dated from 1987 to 2019 were included. Several study designs were employed including think-aloud protocol, interview and written documentation. More than half of the articles analyzed the data using qualitative coding. Authors often utilized several middle-range theories to explain therapeutic reasoning processes. The hypothetico-deductive model was most frequently mentioned. The included articles rarely built off the results from previous studies. Six key result categories were found: identifying themes, characterizing and testing previous local theory, exploring factors, developing new local theory, testing tools, and testing hypothesis. Despite the cast body of therapeutic reasoning research, individual study results remain isolated from previous studies. Our future recommendations include synthesizing pre-existing models, developing novel methodologies, and investigating other aspects of therapeutic reasoning.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    患者偏爱的音乐通常是受版权保护的音乐;先前的研究,然而,很少注意音乐治疗师对版权音乐的理解和使用。为了填补文献中的空白,这项探索性研究试图了解音乐治疗师的经验和对版权音乐的允许治疗用途的看法。对在美国工作的18位获得董事会认证的音乐治疗师进行了半结构化访谈。总的来说,这些参与者拥有超过300年的专业经验。使用归纳的主题分析方法对访谈笔录进行了分析。确定了五个主要主题:(1)版权问题造成了复杂的心理负担;(2)需要使用受版权保护的音乐的治疗需求;(3)对使用受版权保护的音乐的允许治疗实践的看法有所不同;(4)不同的来源了解版权法;(5)需要版权清晰度以减轻心理负担。这些主题表明,版权的不确定性以及参与者试图满足不同利益和保护多个利益相关者的努力产生了心理压力。包括患者,雇主,他们的职业,和法律。我们的发现表明,对版权音乐的允许使用缺乏明确性会使音乐治疗师对适当治疗干预的决策变得复杂。明确允许的音乐治疗用途可以为音乐治疗师带来好处,病人,和社区。
    Patient-preferred music is often copyrighted music; prior research, however, has paid scant attention to music therapists\' understanding and use of copyrighted music. To fill a gap in the literature, this exploratory study sought to understand music therapists\' experiences and perceptions about permissible therapeutic uses of copyrighted music. Semi-structured interviews were conducted with 18 board-certified music therapists working in the United States. Collectively, these participants had over 300 years of professional experience. The interview transcripts were analyzed using an inductive approach to thematic analysis. Five main themes were identified: (1) copyright concerns created a complex psychological burden; (2) therapeutic needs warranted use of copyrighted music; (3) perceptions varied on permissible therapeutic practices using copyrighted music; (4) varied sources informed an understanding of copyright law; and (5) copyright clarity was needed to reduce the psychological burden. These themes suggest that psychological stress was produced by copyright uncertainty coupled with attempts by participants to satisfy diverse interests and protect multiple stakeholders, including patients, employers, their profession, and the law. Our findings suggest that a lack of clarity about permissible uses of copyrighted music can complicate music therapists\' decision-making about appropriate therapeutic interventions. Clarity on permissible therapeutic uses of music could yield benefits for music therapists, patients, and the community.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:探讨全身对比增强CT和肝胆造影肝脏MRI在肝细胞癌(HCC)肝外疾病(EHD)检测中的应用,并量化EHD对治疗决策的影响。方法:在对前瞻性II期开放标签的事后分析中,多中心,随机对照SORAMIC试验,两名盲读者独立分析了538例HCC患者的全身对比增强CT和gadoxetic酸增强肝脏MRI数据集.使用多参数统计测试比较了两种成像方式的EHD(定义为肝外肿瘤表现)的检出率。此外,最适当的治疗建议由事实小组决定.结果:在门静脉浸润患者中检测到EHD的频率明显更高(21%vs.10%,p<0.001),大血管浸润(22%vs.9%,p<0.001),和双叶肝脏受累(18%vs.9%,p=0.006)。更进一步,EHD患者的最大病变直径明显更高(8.2cmvs.5.8cm,p=0.002)。在两个阅读器组中,CT检测到EHD的患者明显多于MRI(p<0.001)。由于EHD主要存在于局部晚期HCC患者中,CT中EHD的较高检出率仅导致一名患者的管理发生变化。其中姑息治疗是护理的标准。结论:全身对比增强CT显示EHD检出率明显高于肝胆对比肝脏MRI。然而,较高的检出率并未对晚期HCC患者管理产生显著影响.
    Background: To investigate whole-body contrast-enhanced CT and hepatobiliary contrast liver MRI for the detection of extrahepatic disease (EHD) in hepatocellular carcinoma (HCC) and to quantify the impact of EHD on therapy decision. Methods: In this post-hoc analysis of the prospective phase II open-label, multicenter, randomized controlled SORAMIC trial, two blinded readers independently analyzed the whole-body contrast-enhanced CT and gadoxetic acid-enhanced liver MRI data sets of 538 HCC patients. EHD (defined as tumor manifestation outside the liver) detection rates of the two imaging modalities were compared using multiparametric statistical tests. In addition, the most appropriate treatment recommendation was determined by a truth panel. Results: EHD was detected significantly more frequently in patients with portal vein infiltration (21% vs. 10%, p < 0.001), macrovascular infiltration (22% vs. 9%, p < 0.001), and bilobar liver involvement (18% vs. 9%, p = 0.006). Further on, the maximum lesion diameter in patients with EHD was significantly higher (8.2 cm vs. 5.8 cm, p = 0.002). CT detected EHD in significantly more patients compared to MRI in both reader groups (p < 0.001). Higher detection rates of EHD in CT led to a change in management only in one patient since EHD was predominantly present in patients with locally advanced HCC, in whom palliative treatment is the standard of care. Conclusions: Whole-body contrast-enhanced CT shows significantly higher EHD detection rates compared to hepatobiliary contrast liver MRI. However, the higher detection rate did not yield a significant impact on patient management in advanced HCC.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Case Reports
    本文重点介绍了病情已长期转向的晚期癌症患者的特殊情况。我们认为,这种慢性有时属于循证医学的前沿,因为对患者病情的不确定性可能导致医生诉诸临床试验或未经许可的药物来防止疾病的进展。这种情况为患者和医生之间的个人调整留下了很大的余地。在这里,晚期癌症不仅被视为生物学事件,而且被视为慢性疾病和“协商现实”。我们认为,晚期癌症患者的慢性状况拓宽了患者的工作范围,我们把这种特定类型的病人的工作称为“决策工作”。本文基于一个案例研究,重点是帕特里克,一名患有转移性肺癌的中年法国人接受了7年的肿瘤治疗,并决心寻找新的治疗选择,即使这意味着必须出国。他通过重新组织与医学界的关系并协调医生的工作,积极地安排了他的治疗行程。他的特殊社会地位使帕特里克绕过了一些现行的医疗规则,并重新组织了通常的医疗责任分配模式。他的病情的长期性使他处于医疗保健系统的前沿。
    This paper focuses on the particular situation of an advanced cancer patient whose condition has taken a chronic turn. We argue that chronicity of this kind sometimes falls at the frontier of Evidence Based Medicine because the uncertainty about the patient\'s condition can lead physicians to resort to clinical trials or non-licensed drugs to prevent the disease from progressing. This situation leaves plenty of scope for individual adjustments between patients and their doctors. Advanced cancer is regarded here not just as a biological event but as a chronic illness and a \'negotiated reality\'. We argue that the chronicity of advanced cancer patients\' situation broadens the patients\' scope for \'work\', and we have called this specific type of patient\'s work \'decision-making work\'. This paper is based on a case study focusing on Patrick, a middle-aged Frenchman with metastatic lung cancer who underwent oncological treatment for seven years and was strongly determined to find new therapeutic options even if this meant having to go abroad. He actively orchestrated his therapeutic itinerary by reorganising his relationships with the medical world and coordinating the physicians\' work. His particular social position enabled Patrick to bypass some of the current medical rules and to reorganise the usual pattern of distribution of medical responsibilities. The chronicity of his condition placed him at the very frontier of the health care system.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    复发性多发性硬化症(RMS)在患者中呈现高度可变的临床演变,它的管理应该是个性化的。虽然目前还没有治愈的方法,有效的疾病改善疗法(DMT)是可用的。为每位患者选择最合适的DMT受几个临床因素的影响,放射学和人口统计方面以及个人偏好,有时,不包括在监管标准中。这可能是困难的根源,特别是在某些情况下,所谓的“高效DMT”(通常被认为是二线)可能对患者有更大的益处。在这篇叙述性评论中,我们讨论证据和经验,并根据专家意见,就成人RMS患者的高疗效DMT的适应证和管理提出务实的决策指导。
    Relapsing multiple sclerosis (RMS) presents a highly variable clinical evolution among patients, and its management should be personalized. Although there is no cure at present, effective disease-modifying therapies (DMTs) are available. Selection of the most appropriate DMT for each patient is influenced by several clinical, radiological and demographic aspects as well as personal preferences that, at times, are not covered in the regulatory criteria. This may be a source of difficulty, especially in certain situations where so-called \'high-efficacy DMTs\' (usually considered second-line) could be of greater benefit to the patient. In this narrative review, we discuss evidence and experience, and propose a pragmatic guidance on decision-making with respect to the indication and management of high-efficacy DMT in adult patients with RMS based on expert opinion.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Case Reports
    Membranous glomerulonephritis is one of the common causes of nephrotic syndrome in the adult population. It is idiopathic in the majority of patients, but the secondary forms can be seen in the setting of autoimmune disease, cancer, infection, and following exposure to certain medications. However, subclinical syphilis-related membranous nephropathy remains a particularly rare clinicopathologic entity in modern times. In this article, we chronicle an interesting case of latent syphilis masquerading as membranous glomerulonephritis, which resolved with benzathine penicillin without requiring immunosuppressive treatment. We further supplement this paper with a concise review of the relevant literature that delineates the utility of appropriate antibiotic therapy in the management of luetic membranous nephropathy. Clinicians should remain cognizant of secondary syphilis while evaluating patients for possible glomerulonephritis or those presenting with proteinuria. Additionally, patients with hepatitis B, hepatitis C, and human immunodeficiency virus infections are not infrequently coinfected with Treponema pallidum. Therefore, a high index of suspicion for systemic manifestations of syphilis such as nephrotic syndrome is warranted in the setting of a coinfection. Prompt diagnosis and treatment of syphilis may result in resolution of proteinuria, without the need for standard immunosuppressive therapy commonly used in clinical practice.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    Allograft rejection-related acute and chronic heart failure (HF) is a major cause of death in heart transplant recipients. Given the deleterious impact of late recognized acute rejection (AR) or non-recognized asymptomatic antibody-mediated rejection on short- and long-term allograft function improvement of AR surveillance and optimization of action strategies for confirmed AR can prevent AR-related allograft failure and delay the development of cardiac allograft vasculopathy, which is the major cause for HF after the first posttransplant year. Routine non-invasive monitoring of cardiac function can improve both detection and functional severity grading of AR. It can also be helpful in guiding the anti-AR therapy and timing of routine surveillance endomyocardial biopsies (EMBs). The combined use of EMBs with non-invasive technologies and methods, which allow detection of subclinical alterations in myocardial function (e.g., tissue Doppler imaging and speckle-tracking echocardiography), reveal alloimmune activation (e.g., screening of complement-activating donor-specific antibodies and circulating donor-derived cell-free DNA) and help in predicting the imminent risk of immune-mediated injury (e.g., gene expression profiling, screening of non-HLA antibodies, and circulating donor-derived cell-free DNA), can ensure the best possible surveillance and management of AR. This article gives an overview of the current knowledge about the reliability and clinical value of non-invasive cardiac allograft AR surveillance. Particular attention is focused on the potential usefulness of non-invasive tools and techniques for detection and functional grading of early and late ARs in asymptomatic patients. Overall, the review aimed to provide a theoretical and practical basis for those engaged in this particularly demanding up-to-date topic.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号